Answers are grounded in this paper and cite their sources.
Objective: We aimed to understand the practices of Turkish urologists using intravesical onabotulinum toxin-A (BoNT-A) injections for refractory overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (NLUTD) treatment, focusing on pre, peri, and postoperative management. We also explored the potential influence of functional urology workload on these practices. Material and Methods: A cross-sectional survey was circulated via the Turkish Association of Urology's WhatsApp group, collecting data on practices and preferences related to BoNT-A treatment. Statistical analysis was performed for comparisons between categorical groups. Results: 65 urologists participated. Most targeted population was NLUTD patients (40%). Preoperatively, spinal or general anesthesia was the preferred method (55.4%). For perioperative prophylaxis, second-generation antibiotics were popular (43.1%). BoNT-A dosage typically was 100 units for first OAB application (92.3%), while 200 units for first NLUTD application (70.8%). The injection site was usually the detrusor (44.6%), with most refraining from trigone injections (63.1%). Respondents with the functional urology workload >25%, favored 300 units for the first NLUTD application (p=0.009), trigone injections (p<0.001), and a second application between 3-5 months (p=0.016). Conclusion: Significant variations have been identified in the usage of BoNT-A for the treatment of OAB and NLUTD by Turkish urologists, largely influenced by the functional urology workload. Understanding these differences will help refine treatment strategies and highlight the need for more research and more specific guidelines.
No takes yet. Share an insight, caveat, or question.
Çoşkun et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: